Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors.
dc.contributor.author | Zubairi, I | |
dc.contributor.author | Dean, Emma J | |
dc.contributor.author | Molife, L | |
dc.contributor.author | Lopez, J | |
dc.contributor.author | Ranson, Malcolm R | |
dc.contributor.author | El-Khouly, F | |
dc.contributor.author | Savulsky, C | |
dc.contributor.author | Reyderman, L | |
dc.contributor.author | Jia, Y | |
dc.contributor.author | Hutton, E | |
dc.contributor.author | Morrison, R | |
dc.contributor.author | Sweeting, L | |
dc.contributor.author | Greystoke, A | |
dc.contributor.author | Barriuso, J | |
dc.contributor.author | Kristeleit, R | |
dc.contributor.author | Evans, T | |
dc.date.accessioned | 2016-12-16T15:41:04Z | |
dc.date.available | 2016-12-16T15:41:04Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors. 2016, 39: 206-206 Oncol Res Treat | en |
dc.identifier.uri | http://hdl.handle.net/10541/620052 | |
dc.language.iso | en | en |
dc.title | Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors. | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Beatson West of Scotland Cancer Centre, Glasgow | en |
dc.identifier.journal | Oncology Research and Treatment | en |